Clinical Trial Update: Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study

View source ↗

Summary

This real-world study updates the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive and HER2-low metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Low Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Breast Cancer | Status: COMPLETED